#pcsk9

[oaresearchpaper]

There is increasing evidence in support of a decisive role played by the diet in the development of non-communicable diseases. The present study aimed to assess the effect of salt overfeeding on renal function and on the cardiovascular system in Wistar rats. Four groups of rats were exposed to diets with various salt levels, 0.8% for control, and 2%, 4% and 8% for overfed rats during 12 weeks. Blood Glucose, Triglycerides, Total cholesterol, LDL cholesterol (LDL-c) and HDL cholesterol (HDL-c) levels were determined by enzymatic method and serum PCSK9 by ELISA. Kidneys’ histology sections were treated with hematoxylin-eosin staining. Serum creatinine (17.54±2.35 mg/L vs. 11.06±0.95 mg/L; p

[jakiesun]

PCSK9新藥：幫高風險族群大幅降膽固醇，降低心血管事件

📢簡短摘要 💉【誰最適合考慮？】👉 已有 ASCVD（冠心病💔、中風🧠、周邊動脈病變）或極高風險族群👉 對Statin他汀／Ezetimibe 仍無法達到 LDL 目標者📊 FOURIER、ODYSSEY 大型試驗證實能降低心血管事件風險 ⚖️【選藥考量】⚡ 想「最快、最大幅度」降壞膽固醇 👉 Repatha / Praluent（每月或每2週注射）🕕 想「半年打一針、省事依從性佳」 👉 Leqvio（Inclisiran，每6個月一次）📚 ORION 試驗仍在追蹤長期心血管效益 💰【價格與給付】🌍 國際價格差異大，美國列價動輒上萬美元，但多有折扣計畫🇹🇼 台灣 2025 年健保已放寬給付門檻 ✅— 若符合條件，每月自付約 NT$2,000–3,000— 不符給付者自費可達數十萬／年🩺 建議諮詢主治醫師或藥局了解最新健保規範與補助方案 #膽固醇 #PCSK9 #Repatha…

PCSK9新藥：幫高風險族群大幅降膽固醇，降低心血管事件

[ricercamix]

Aterosclerosi, PCSK9 e vescicole extracellulari

Aterosclerosi, PCSK9 e vescicole extracellulari

Ciao a tutti, mi chiamo Maria Francesca Greco e frequento il terzo anno di dottorato in Scienze Farmacologiche, Biomolecolari, Sperimentali e Cliniche presso l’Università degli Studi di Milano. Come spiegato nel post precedente, l’obiettivo del mio progetto è stato quello di valutare l’effetto della proproteina convertasi subtilisina/kexina di tipo 9 (PCSK9) sulle proprietà biologiche e…

View On WordPress

[neerthirai24]

Cholesterol Lowering Medications are Used to Treat Danes

Cholesterol Lowering Medications are Used to Treat Danes

This discovery makes it possible to develop potentially more efficient and also cheaper PCSK9 inhibiting medicine, which is the new hope for cholesterol treatment. ‘PCSK9 is captured by specific molecules in the liver called heparan sulfate proteoglycans (HSPG), which subsequently lead to the breaking down of the LDL receptor.’ “Statins save many lives every year, but the medicine has the…

View On WordPress

[ricercamix]

Le vescicole extracellulari e le componenti dell’aterosclerosi

Ciao a tutti, mi chiamo Maria Francesca Greco e sono al primo anno di dottorato in Scienze Farmacologiche Biomolecolari, Sperimentali e Cliniche presso l’Università degli Studi di Milano. I principali obiettivi del mio progetto di ricerca sono quello di valutare il ruolo delle vescicole extracellulari nel contesto dell’aterosclerosi e come la proteina PCSK9 (proproteina convertasi…

View On WordPress

[ricercamix]

PCSK9 e metabolismo lipidico

PCSK9 e metabolismo lipidico

Mi chiamo Laura, sono laureata in Chimica e Tecnologia Farmaceutiche all’Università degli Studi di Milano. Ho iniziato da poco il mio secondo anno di dottorato in Scienze Farmacologiche Biomolecolari, Sperimentali e Cliniche e svolgo la mia attività di ricerca presso il laboratorio di Dislipidemia Genetica ed Aterosclerosi dell’I.R.C.C.S. MultiMedica. Oggetto della mia ricerca è PCSK9…

View On WordPress

[fromsciencetopharma]

AstraZeneca acquires Dogma’s oral PCSK9 inhibitor programme #Astrazeneca #PCSK9 “The pharma major plans to advance the PCSK9 inhibitor programme into clinical development for #dyslipidaemia and #familialhypercholesterolemia in 2021. Dyslipidaemia is a condition in which there is abnormal amount of lipids like low-density lipoprotein (LDL cholesterol) or bad cholesterol present in the blood. On the other hand, familial hypercholesterolemia is a common genetic condition that leads to high cholesterol. According to AstraZeneca, PCSK9 is a protein that controls the LDL cholesterol levels in the blood. Heightened activity of the protein is related to high LDL cholesterol, said the company. The acquired PCSK9 inhibitors by AstraZeneca are small molecules which directly bind to a novel part of the protein. In preclinical models, the inhibitors have shown to prevent the protein’s activity and had resulted in lower LDL cholesterol. Presently, there are no oral inhibitors of the protein that are either available to patients or in clinical development, said the pharma major. https://www.instagram.com/p/CFX4am1j8v3/?igshid=fqf75cs002dj

[afreelancers-aide-memoire]

PCSK9 enzyme

Proprotein Convertase Subtilisin/Kexin type 9

It is the ninth member of Subtilisin protease family.

It plays a major regulatory role in cholesterol hemostatsis.

It is an enzyme that binds to low-density lipoprotein receptors (LDL receptors), which stops LDL being removed from the blood, leading to an increase in blood levels of LDL. 

The PCSK9 inhibitor [Alirocumab &  Evolocumab] blocks the PCSK9 enzyme, resulting in more LDL receptors available to remove LDL from the blood, which produces in a decrease in LDL blood levels.

Impact of PCSK9 inhibitors treatment:

↓ LDL cholesterol (50-60%)

↓ triglycerides  (8-20%)

↓ total cholesterol (25-40%)

↑ HDL cholesterol (5-9%)